Effect of Peripheral Arterial Disease in Patients Undergoing Percutaneous Coronary Intervention With Intracoronary Stents

Singh, Mandeep; Lennon, Ryan J.; Dawood Darbar; Gersh, Bernard J.; Holmes Jr, David R.; Rihal, Charanjit S.
September 2004
Mayo Clinic Proceedings;Sep2004, Vol. 79 Issue 9, p1113
Academic Journal
The article reports a study on the effect of peripheral arterial disease (PAD) in patients undergoing percutaneous coronary intervention with intracoronary stents. This study showed that patients with coronary artery disease and PAD who were treated with intracoronary stents had lower procedural success and higher in-hospital complications, including higher blood loss requiring transfusions, compared with patients who had isolated coronary artery disease but no PAD. PAD is an independent risk factor for short-term and long-term adverse cardiovascular outcomes, with higher mortality, myocardial infarction, and need for repeated target vessel revascularization. Results of percutaneous coronary intervention in patients with PAD in recent years have improved.


Related Articles

  • Renal function after hybrid operation in patients with multifocal atherosclerosis mainly affecting the coronary and carotid arteries. KANDAUROV, A. EH.; CHVOKOV, A. V. // Kardiologia i Serdechno-Sosudistaya Khirurgia;2014, Vol. 7 Issue 2, p74 

    It was studied renal function in patients with ischemic heart disease and carotid arteries lesions after open heart operation and stenting of carotid arteries. It was shown that risk of renal dysfunction in postoperative period in patients' group with cardiopulmonary bypass was higher than in...

  • Tratamiento quirúrgico de un aneurisma de la arteria innominada: hallazgo incidental en una revascularización miocárdica. Ferreira-Piña, Benigno; Ramírez-Castañeda, Serafín; Prado-Villegas, Guillermo; Careaga-Reyna, Guillermo; Argüero-Sánchez, Rubén // Cirugia y Cirujanos;ene/feb2009, Vol. 77 Issue 1, p57 

    Innominate artery aneurysms are an uncommon pathology. There are several pathogenic mechanisms involved in their formation, and patients are usually asymptomatic. However, different clinical presentations are possible. Management varies according to anatomic characteristics. Surgical treatment...

  • Mechanical reperfusion therapy for acute myocardial infarction: Stent PAMI, ADMIRAL, CADILLAC and beyond. Brodie, B. R.; Stuckey, T. D. // Heart;Mar2002, Vol. 87 Issue 3, p191 

    Mechanical reperfusion has gained increasing acceptance as a reperfusion strategy for acute myocardial infarction as a result of data from numerous randomised trials showing superior outcomes. Recently, the stent PAMI, ADMIRAL, and CADILLAC trials have documented further improvement in outcomes...

  • Vascular Stenting vs. Bypass for Multivessel Disease. Zepf, Bill // American Family Physician;11/1/2001, Vol. 64 Issue 9, p1613 

    Presents information on a study by P.W. Serruys and others on the issue of endovascular versus open-heart surgery for treatment of multivessel coronary artery disease. Description of the study and its results; Conclusion that stenting is less expensive than bypass grafting and not associated...

  • What reimbursement for coronary revascularization with drug-eluting stents? Tarricone, Rosanna; Marchetti, Monia; Lamotte, Mark; Annemans, Lieven; de Jong, Peter // European Journal of Health Economics;Dec2004, Vol. 5 Issue 4, p309 

    We investigated the clinical and economic impact of sirolimus-eluting coronary stents (SES) at a nationwide level as to advice about the feasible reimbursement policy for the Italian Health Care System (SSN). A decision model compared bare metal stents (BMS) and SES in terms of costs and repeat...

  • Role of stenting in coronary revascularisation. Gershlick, Anthony H. // Heart;Jul2001, Vol. 86 Issue 1, p104 

    Percutaneous treatment for atheromatous coronary disease has developed rapidly in the last 5-10 years. Some technologies, such as laser therapy, have fallen by the wayside as clinical trials and clinical experience demonstrates lack of efficacy or excess complications. Others devices such as...

  • Novel bioabsorbable stents are a pace apart. Pinn, Stephen // British Journal of Hospital Medicine (17508460);Apr2008, Vol. 69 Issue 4, p189 

    The article presents a study of a novel bioabsorbable drug-eluting stent for patients with single de-novo coronary artery lesions. The rate of major adverse cardiac events was 3.3%, with only one patient having a non-Q-wave myocardial infarction and no target lesion revascularization at year...

  • Comparison of an Everolimus-Eluting Stent and a Paclitaxel-Eluting Stent in Patients With Coronary Artery Disease. Stone, Gregg W.; Midei, Mark; Newman, William; Sanz, Mark; Hermiller, James B.; Williams, Jerome; Farhat, Naim; Mahaffey, Kenneth W.; Cutlip, Donald E.; Fitzgerald, Peter J.; Sood, Poornima; Xiaolu Su; Lansky, Alexandra J. // JAMA: Journal of the American Medical Association;4/23/2008, Vol. 299 Issue 16, p1903 

    The article presents a study comparing the angiographic outcomes in coronary artery disease patients using everolimus-eluting verses those using paclitaxel-eluting stents. The objectives, design and setting of the controlled patient trial are defined. Research showed that the everolimus stent...

  • 2016 - PCI with drug-eluting stents reduced revascularizations, but not mortality or MI, compared with bare-metal stents. Hudson, Michael // ACP Journal Club;11/15/2016, Vol. 165 Issue 10, p1 

    Question In patients with coronary artery disease (CAD) who are having percutaneous coronary intervention (PCI), what are the relative efficacies and harms of newer-generation drug-eluting stents (DESs) and bare-metal stents (BMSs)? Methods Design Randomized controlled trial (RCT) (Norwegian...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics